Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab PRN monotherapy for macular edema secondary to central retinal vein occlusion
NL-OMON37905Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in central retinal vein occlusion (CRVO) and macular edema, sponsored by Novartis. Primary endpoint: Mean change in best-corrected visual acuity at Month 12 from Baseline. Started Jul 2012; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion (CRVO)macular edema
Beyond the preview
Go deeper on NL-OMON37905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37905.